| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Biochemistry and Biophysics |
Departments of Pathology [L. S., A. P.] and Biochemistry and Molecular Biology [M. V., A. P.], and the Greenebaum Cancer Center Program in Oncology and Experimental Therapeutics [L. S., A. P.], University of Maryland School of Medicine, Baltimore, Maryland 21201
Understanding the regulation of endothelial cell (EC) gene expression has important implications for angiogenesis, tumor growth, and metastasis. The transcription factor runt-related gene 2 (RUNX2)/core binding factor
-1/acute myeloid leukemia 3/polyoma enhancer-binding protein 2
A/osteoblast-specific transcription factor 2 regulates osteoblast differentiation, increases lymphomagenesis in transgenic mice, and is expressed in murine ECs. Here, we report on RUNX2 expression in human bone marrow EC (HBME-1) and its role in EC differentiation. Expression of RUNX2 occurred in HBME-1 cultured on extracellular matrix (ECM) substrates that stimulate in vitro differentiation (tube formation). Neutralizing anti-insulin-like growth factor (IGF)-I-receptor antibody inhibited tube formation as well as activation of RUNX2 expression in HBME-1 cultured on ECM. IGF-I treatment also increased both RUNX2 mRNA and protein expression. HBME-1 transfectants expressing dominant-negative (DN) RUNX were established to address the role of RUNX2 in these processes. HBME/DN cells exhibited reduced tube formation activity relative to control transfectants and less ability to growth arrest and differentiate on ECM. DNRUNX expression also inhibited HBME-1 migration and invasion, which are necessary for tube formation. The urokinase-type plasminogen activator and membrane-type MMP-1 genes were consistently down-regulated in DNRUNX transfectants. The results suggest that RUNX2 is important in IGF-I and ECM-regulated EC migration and differentiation. RUNX2 effects on HBME-1 migration and invasion may occur through activation of protease expression, events that regulate angiogenesis, and tumor growth.
This article has been cited by other articles:
![]() |
X. Sun, L. Wei, Q. Chen, and R. M. Terek HDAC4 Represses Vascular Endothelial Growth Factor Expression in Chondrosarcoma by Modulating RUNX2 Activity J. Biol. Chem., August 14, 2009; 284(33): 21881 - 21890. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Gupta, R. S. Papay, C. W. D. Jurgens, R. J. Gaivin, T. Shi, V. A. Doze, and D. M. Perez {alpha}1-Adrenergic Receptors Regulate Neurogenesis and Gliogenesis Mol. Pharmacol., August 1, 2009; 76(2): 314 - 326. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. D'Souza, M. M. Salib, J. Bennett, M. Mochin-Peters, K. Asrani, S. E. Goldblum, K. J. Renoud, P. Shapiro, and A. Passaniti Hyperglycemia Regulates RUNX2 Activation and Cellular Wound Healing through the Aldose Reductase Polyol Pathway J. Biol. Chem., July 3, 2009; 284(27): 17947 - 17955. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Liu, E.-S. Park, and M. Jo Runt-Related Transcription Factor 1 Regulates Luteinized Hormone-Induced Prostaglandin-Endoperoxide Synthase 2 Expression in Rat Periovulatory Granulosa Cells Endocrinology, July 1, 2009; 150(7): 3291 - 3300. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H. Licht, O. T. Pein, L. Florin, B. Hartenstein, H. Reuter, B. Arnold, P. Lichter, P. Angel, and M. Schorpp-Kistner JunB is required for endothelial cell morphogenesis by regulating core-binding factor {beta} J. Cell Biol., December 18, 2006; 175(6): 981 - 991. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hamik, B. Wang, and M. K. Jain Transcriptional Regulators of Angiogenesis Arterioscler Thromb Vasc Biol, September 1, 2006; 26(9): 1936 - 1947. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Qiao, P. Shapiro, M. Fosbrink, H. Rus, R. Kumar, and A. Passaniti Cell Cycle-dependent Phosphorylation of the RUNX2 Transcription Factor by cdc2 Regulates Endothelial Cell Proliferation J. Biol. Chem., March 17, 2006; 281(11): 7118 - 7128. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Pratap, A. Javed, L. R. Languino, A. J. van Wijnen, J. L. Stein, G. S. Stein, and J. B. Lian The Runx2 Osteogenic Transcription Factor Regulates Matrix Metalloproteinase 9 in Bone Metastatic Cancer Cells and Controls Cell Invasion Mol. Cell. Biol., October 1, 2005; 25(19): 8581 - 8591. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Habtemariam, V. M. Anisimov, and A. D. MacKerell Jr Cooperative binding of DNA and CBF{beta} to the Runt domain of the CBF{alpha} studied via MD simulations Nucleic Acids Res., July 26, 2005; 33(13): 4212 - 4222. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Qiao, P. Shapiro, R. Kumar, and A. Passaniti Insulin-like Growth Factor-1 Regulates Endogenous RUNX2 Activity in Endothelial Cells through a Phosphatidylinositol 3-Kinase/ERK-dependent and Akt-independent Signaling Pathway J. Biol. Chem., October 8, 2004; 279(41): 42709 - 42718. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. L. Barnes, K. E. Hebert, M. Kamal, A. Javed, T. A. Einhorn, J. B. Lian, G. S. Stein, and L. C. Gerstenfeld Fidelity of Runx2 Activity in Breast Cancer Cells Is Required for the Generation of Metastases-Associated Osteolytic Disease Cancer Res., July 1, 2004; 64(13): 4506 - 4513. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. K. Inman and P. Shore The Osteoblast Transcription Factor Runx2 Is Expressed in Mammary Epithelial Cells and Mediates osteopontin Expression J. Biol. Chem., December 5, 2003; 278(49): 48684 - 48689. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |